In:
BJU International, Wiley, Vol. 112, No. 2 ( 2013-07), p. 246-257
Abstract:
To study PDE 5 localisation by visualising the product of phosphodiesterase type 5 ( PDE 5) inhibition, namely cGMP , to determine the site of action of inhibitors in the urinary bladder. Materials and Methods Bladders of nine male guinea pigs were dissected and treated in wells containing 2 mL K rebs' solution and 1 μM of the specific PDE 5 inhibitor vardenafil at 36 ° C for 30 min. After stimulating tissues with 100 μM of the nitric oxide ( NO ) donor diethylamine‐ NONO ate for 10 min, the tissues were snap‐frozen and 9–10 μm sections were cut. Sections were examined for cGMP immunoreactivity and also stained for vimentin, a marker for interstitial cells and the neuromarkers protein gene product 9.5 ( PGP 9.5), synaptic vesicle protein 2 ( SV 2), neurofilament ( NF ) and calcitonin gene‐related peptide ( CGRP ), using the two‐step indirect immunohistochemistry technique. Results After PDE 5 inhibition, cGMP was found to be present in the urothelium, suburothelial interstitial cells and endothelium of blood vessels. cGMP was not expressed in nerves positive for CGRP , NF and SV 2, and was expressed only in very few efferent nerves positive for PGP 9.5. Conclusion Our data show that the possible sites of action of PDE 5 inhibition in the bladder are the urothelium, suburothelial interstitial cells and blood vessels, rather than the bladder nerve fibres.
Type of Medium:
Online Resource
ISSN:
1464-4096
,
1464-410X
DOI:
10.1111/bju.2013.112.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2019983-1
Bookmarklink